GleamWall
中文EN

AXSM Axsome Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1579428 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY54.2%
TTM net income YoY31.5%
TTM EPS YoY35.1%
Revenue 3-yr CAGR57.0%
Net income 3-yr CAGR—

Margins

Gross margin93.2%
Operating margin-17.5%
Net margin-18.2%
FCF margin-9.5%
EBITDA margin-17.4%

Returns

ROE-175.6%
ROA-21.0%
ROIC (approx.)—
Asset turnover1.16x

Leverage & solvency

Liabilities / assets87.2%
Debt / equity1.78x
Current ratio1.42x
Interest coverage22.43x

Cash quality & payout

Operating cash flow / net income0.52x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$638.50M$385.69M
Cost of revenue$47.48M$33.30M
Gross profit$591.02M$352.39M
R&D expense$183.28M$187.08M
SG&A expense$570.60M$411.36M
Operating income-$166.76M-$280.56M
Interest expense-$15.93M-$21.58M
Pretax income-$183.70M-$287.13M
Income tax-$530,000$85,000
Net income-$183.17M-$287.22M
EBITDA-$166.26M-$280.03M
EPS (basic)-3.68-5.99
EPS (diluted)-3.68-5.99
Weighted avg. shares (diluted)49.75M47.91M
Balance sheet
Cash & equivalents$322.93M$315.35M
Receivables$224.46M$142.00M
Inventory$27.94M$15.73M
Current assets$588.99M$485.06M
PP&E, net$562,000$584,000
Goodwill$12.04M$12.04M
Intangibles$40.52M$46.89M
Total assets$689.80M$568.50M
Current liabilities$378.84M$230.10M
Short-term debt$70.00M$0
Long-term debt$117.75M$180.71M
Total debt$187.75M$180.71M
Total liabilities$601.51M$511.48M
Shareholders' equity$88.30M$57.02M
Net debt-$135.19M-$134.64M
Shares outstanding50.88M48.67M
Cash flow statement
Operating cash flow-$93.41M-$128.41M
Capital expenditure$480,000$270,000
Free cash flow-$93.89M-$128.68M
Investing cash flow-$480,000-$270,000
Financing cash flow$101.47M$57.84M
Depreciation & amortization$503,000$532,000
Stock-based compensation$93.75M$85.22M

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.